Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donor

Leuk Lymphoma. 2019 Dec;60(14):3573-3576. doi: 10.1080/10428194.2019.1636981. Epub 2019 Jul 18.

Authors

Patrick-Pascal Strunz¹, Marc Schmalzing¹, Anke Heidemeier², Leo Rasche¹, Hermann Einsele¹, K Martin Kortüm¹

Affiliations

¹ Universitatsklinikum Wurzburg, Medizinische Klinik und Poliklinik II, Wurzburg, Germany.
² Universitatsklinikum Würzburg, Radiologie, Wurzburg, Germany.

PMID: 31317812
DOI: 10.1080/10428194.2019.1636981

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / therapeutic use
Antineoplastic Agents, Immunological / pharmacology
Drug Resistance, Neoplasm / drug effects*
Epstein-Barr Virus Infections / complications*
Epstein-Barr Virus Infections / virology
Hematopoietic Stem Cell Transplantation / adverse effects*
Herpesvirus 4, Human / isolation & purification
Humans
Lymphoproliferative Disorders / drug therapy*
Lymphoproliferative Disorders / etiology
Lymphoproliferative Disorders / pathology
Male
Middle Aged
Multiple Myeloma / pathology
Multiple Myeloma / therapy*
Multiple Myeloma / virology
Prognosis
Rituximab / pharmacology*

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Antineoplastic Agents, Immunological
Rituximab
daratumumab